Back to News
Market Impact: 0.2
Saving Heart Muscle After a Heart Attack: Nature Reports PeriFlow's First-in-Class Capillary-Selective Vasodilator
Source: PR Newswire
Healthcare & BiotechTechnology & Innovation
PeriFlow Therapeutics is advancing CLN-2501, a first-in-class candidate intended to restore capillary blood flow after acute myocardial infarction by targeting capillary no-reflow. The program is moving toward clinical development in the US; the article provides no trial timing, clinical results, or financial figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
More News
- Why is Samsung Electronics stock plunging today?
- SK Hynix plunges 8% amid Asia tech rout as Fed rate hike fears, AI funding worries mount
- Elon Musk says Trump is 'ultimately' responsible for any curbs on Ukraine's Starshield systems
- SK Hynix seeks U.S. chip equipment exports to China tied to new factory
- Dell stock plunges 11%, leading data center sell-off on concerns about 'enterprise AI timing'
- Why is Rocket Lab stock tumbling today?